What is HC Wainwright’s Estimate for AXSM FY2026 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a research report issued to clients and investors on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $3.91 for the year, up from their previous estimate of $3.72. HC Wainwright has a “Buy” rating and a $260.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2026 earnings at $2.06 EPS.

Other equities research analysts have also issued research reports about the company. Robert W. Baird set a $209.00 target price on Axsome Therapeutics in a research report on Tuesday, January 13th. B. Riley began coverage on shares of Axsome Therapeutics in a research note on Wednesday, October 1st. They set a “buy” rating and a $179.00 price objective for the company. Piper Sandler increased their price objective on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Guggenheim restated a “buy” rating and set a $205.00 target price on shares of Axsome Therapeutics in a research report on Friday, January 2nd. Finally, Wells Fargo & Company upped their price target on shares of Axsome Therapeutics from $157.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday, January 13th. Nineteen research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $203.17.

Axsome Therapeutics Stock Up 2.5%

Axsome Therapeutics stock opened at $189.10 on Wednesday. The business’s 50-day simple moving average is $157.48 and its two-hundred day simple moving average is $132.17. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The company has a market cap of $9.53 billion, a PE ratio of -40.49, a PEG ratio of 9.73 and a beta of 0.44. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $189.34.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The firm’s quarterly revenue was up 63.2% on a year-over-year basis.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently bought and sold shares of AXSM. Vanguard Group Inc. lifted its position in shares of Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after acquiring an additional 235,626 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after purchasing an additional 609,516 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Axsome Therapeutics by 73.3% during the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after buying an additional 419,008 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Axsome Therapeutics by 5.8% in the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock valued at $103,303,000 after buying an additional 54,600 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Axsome Therapeutics by 5.8% in the second quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after buying an additional 52,483 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the sale, the director owned 10,002 shares in the company, valued at $1,652,130.36. This trade represents a 78.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $956,685.86. This represents a 92.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 420,903 shares of company stock worth $63,552,838 in the last quarter. Insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.